Authors
Christian Steidl, Tang Lee, Sohrab P Shah, Pedro Farinha, Guangming Han, Tarun Nayar, Allen Delaney, Steven J Jones, Javeed Iqbal, Dennis D Weisenburger, Martin A Bast, Andreas Rosenwald, Hans-Konrad Muller-Hermelink, Lisa M Rimsza, Elias Campo, Jan Delabie, Rita M Braziel, James R Cook, Ray R Tubbs, Elaine S Jaffe, Georg Lenz, Joseph M Connors, Louis M Staudt, Wing C Chan, Randy D Gascoyne
Publication date
2010/3/11
Journal
New England Journal of Medicine
Volume
362
Issue
10
Pages
875-885
Publisher
Massachusetts Medical Society
Description
Background
Despite advances in treatments for Hodgkin's lymphoma, about 20% of patients still die from progressive disease. Current prognostic models predict the outcome of treatment with imperfect accuracy, and clinically relevant biomarkers have not been established to improve on the International Prognostic Score.
Methods
Using gene-expression profiling, we analyzed 130 frozen samples obtained from patients with classic Hodgkin's lymphoma during diagnostic lymph-node biopsy to determine which cellular signatures were correlated with treatment outcome. We confirmed our findings in an independent cohort of 166 patients, using immunohistochemical analysis.
Results
Gene-expression profiling identified a gene signature of tumor-associated macrophages that was significantly associated with primary treatment failure (P=0.02). In an independent cohort of patients, we found that an increased …
Total citations
Scholar articles
C Steidl, T Lee, SP Shah, P Farinha, G Han, T Nayar… - New England Journal of Medicine, 2010